Chemistry:BMS-202
From HandWiki
BMS-202 is a small-molecule drug PD-L1 inhibitor developed by Bristol-Myers Squibb which displays significant anti-tumor activity against glioblastoma (GBM) cells.[1] In addition, BMS-202 has an inhibitory effect on both PD-L1-expressing cancer cells and activated T cells.[2]
References
- ↑ "BMS-202, a PD-1/PD-L1 inhibitor, decelerates the pro‑fibrotic effects of fibroblasts derived from scar tissues via ERK and TGFβ1/Smad signaling pathways". Immunity, Inflammation and Disease 10 (10): e693. 2022. doi:10.1002/iid3.693. PMID 36169254.
- ↑ "Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse". Biomedical Research 40 (6): 243–250. 2019. doi:10.2220/biomedres.40.243. PMID 31839668.
Template:PD-1 and PD-L1 inhibitors
 |  |
